By completing this transition, the Company now manufactures its entire NanoVibronix line in the United States, leveraging these U.S.-based operations to establish a stronger foundation for long-term growth and strategic expansion.

The NanoVibronix product line comprises the Company’s acoustic-based therapeutic technologies, including PainShield® and UroShield®, which utilize proprietary low-intensity surface acoustic wave (SAW) technology and are intended for use in home or care settings.

"Completing the transition of our NanoVibronix product line manufacturing to the United States marks the achievement of a major strategic operational initiative for the Company," said Doron Besser, MD, CEO of ENvue Medical. "By consolidating our manufacturing operations domestically, we expect to improve operational efficiency, reduce costs, and streamline supply chain management, while enhancing operational oversight as we continue to grow."

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.